GATA2 deficiency was first identified in 2011 and have been reported over 500 individuals with GATA2 mutations. The onset of symptoms ranges from early childhood to late adulthood but very often the diagnosis is made between adolescence and early adulthood. These patients can be relatively asymptomatic or have life threatening diseaseas (myelodysplastic syndrome, acute leukemia). We describe case of 30-years old women with GATA2 novel mutation who present by primary lymphedema, myelodysplastic changes in bone marrow, monocytopenia and history of several recurrent infections (bacterial, mycobacterial). The case illustrates the diagnostic difficulties in identifying GATA2 deficiencies.

4th Department of Internal Medicine Haematology Charles University Hospital Hradec Kralove Czech Republic

Institute of Clinical Biochemistry and Diagnostics Charles University Hospital Hradec Kralove Czech Republic

Zobrazit více v PubMed

Hsu A.P., Sampaio E.P., Khan J., Calvo K.R., Lemieux J.E., Patel S.Y., et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118(10):2653–2655. PubMed PMC

Bresnick E.H., Jung M.M., Katsumura K.R. Human GATA2 mutations and hematologic disease: how many paths to pathogenesis? Blood Adv. 2020;4(18):4584–4592. PubMed PMC

Ostergaard P., Simpson M.A., Connell F.C., Steward C.G., Brice G., Woollard W.J., et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome) Nat Genet. 2011;43(10):929–931. PubMed

Hirabayashi S., Wlodarski M.W., Kozyra E., Niemeyer C.M. Heterogeneity of GATA2-related myeloid neoplasms. Int. J. Hematol. 2017;106(2):175–182. PubMed

Donadieu J., Lamant M., Fieschi C., De Fontbrune F.S., Caye A., Ouachee M.E., et al. Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica. 2018;103(8):1278–1287. PubMed PMC

Wlodarski M.W., Hirabayashi S., Pastor V., Stary J., Hasle H., Masetti R., et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127(11):1387–1397. PubMed

Homan C.C., Venugopal P., Arts P., Shahrin N.H., Feurstein S., Rawlings L., et al. GATA2 deficiency syndrome: a decade of discovery. Hum. Mutat. 2021;42(11):1399–1421. PubMed PMC

McReynolds L.J., Yang Y., Yuen Wong H., Tang J., Zhang Y., Mulé M.P., et al. MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations. Leuk. Res. 2019;76:70–75. PubMed PMC

McReynolds L.J., Zhang Y., Yang Y., Tang J., Mulé M., Hsu A.P., et al. Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation. Leuk. Res. Rep. 2019;10(12) PubMed PMC

Badaat I., Mirza S., Padron E., Sallman D., Komrokji R., Song J., Hussaini M.O. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome. J. Clin. Pathol. 2020;73(4):209–212. PubMed

Ganguly B.B., Kadam N.N. Mutations of myelodysplastic syndromes (MDS): an update. Mutat. Res. Rev. Mutat. Res. 2016;769:47–62. PubMed

McReynolds L.J., Calvo K.R., Holland S.M. Germline GATA2 mutation and bone marrow failure. Hematol. Oncol. Clin. North Am. 2018;32(4):713–728. PubMed PMC

Shen Y., Li Y., Li H., Liu Q., Dong H., Wang B., Ye B., Lin S., Shen Y., Wu D. Diagnosing MonoMAC syndrome in GATA2 germline mutated myelodysplastic syndrome via next-generation sequencing in a patient with refractory and complex infection: case report and literature review. Infect Drug Resist. 2021;6(14):1311–1317. PubMed PMC

Bortnick R., Wlodarski M., de Haas V., De Moerloose B., Dworzak M., Hasle H., et al. Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. Bone Marrow Transplant. 2021;56(11):2732–2741. PubMed PMC

Bogaert D.J., Laureys G., Naesens L., Mazure D., De Bruyne M., Hsu A.P. GATA2 deficiency and haematopoietic stem cell transplantation: challenges for the clinical practitioner. Br. J. Haematol. 2020;188(5):768–773. PubMed